Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04460807 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer(EXPERT) | terminated | Phase 3 | 23 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05189028 | Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer | unknown | Phase 3 | 290 | Chuangzhen ChenOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05564286 | Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer | completed | Phase 3 | 116 | Shantou University Medical CollegeOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06211023 | A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | unknown | Phase 2 / Phase 3 | 520 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Jan 18, 2024 | clinicaltrials |
| NCT04864782 | QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer | terminated | Phase 2 / Phase 3 | 46 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04970368 | Comparison of Nodal Staging in Endometrial Cancer | terminated | Phase 3 | 38 | Frederick R. Ueland, M.D.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06188455 | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | not yet recruiting | Phase 3 | 37 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT05173272 | Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer | recruiting | Phase 3 | 286 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05446324 | Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer(SENGA) | unknown | Phase 3 | 10 | UMC UtrechtOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT00657878 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval(MITO-8) | unknown | Phase 3 | 215 | National Cancer Institute, NaplesOTHER | 3 | Nov 13, 2023 | clinicaltrials |
| NCT00716976 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | completed | Phase 3 | 131 | Children's Oncology GroupNETWORK | 3 | Nov 9, 2023 | clinicaltrials |
| NCT02584478 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)(AL3818) | unknown | Phase 3 | 294 | Advenchen Laboratories, LLCINDUSTRY | 6 | Nov 8, 2023 | clinicaltrials |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | withdrawn | Phase 3 | 0 | EQRx International, Inc.INDUSTRY | 0 | Nov 3, 2023 | clinicaltrials |
| NCT04596800 | Prehabilitation Plus ERAS Versus ERAS in Gynecologic Oncology: a Randomized Clinical Trial(PROPER) | unknown | Phase 3 | 194 | Instituto Brasileiro de Controle do CancerOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer(AXLerate-OC) | terminated | Phase 3 | 366 | Aravive, Inc.INDUSTRY | 11 | Oct 30, 2023 | clinicaltrials |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | terminated | Phase 3 | 20 | Mersana TherapeuticsINDUSTRY | 3 | Oct 26, 2023 | clinicaltrials |
| NCT00411138 | Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer(PORTEC-3) | unknown | Phase 3 | 670 | Leiden UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT03469674 | PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer(PORTEC-4a) | active not recruiting | Phase 3 | 550 | Leiden University Medical CenterOTHER | 8 | Oct 11, 2023 | clinicaltrials |
| NCT01506856 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial(iPocc) | completed | Phase 2 / Phase 3 | 655 | Gynecologic Oncology Trial & Investigation ConsortiumNETWORK | 6 | Sep 15, 2023 | clinicaltrials |
| NCT04311073 | Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies | unknown | Phase 3 | 50 | Eastern Virginia Medical SchoolOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT04989647 | Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy(CERVANTES) | recruiting | Phase 3 | 514 | The Central and Eastern European Gynecologic Oncology GroupOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT02423876 | Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery | completed | Phase 3 | 104 | University of Wisconsin, MadisonOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)(REVEAL 1) | completed | Phase 3 | 201 | Inovio PharmaceuticalsINDUSTRY | 19 | Jul 27, 2023 | clinicaltrials |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | terminated | Phase 3 | 3,131 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT04201561 | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy(SELENIUM) | unknown | Phase 3 | 68 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04782895 | Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age | completed | Phase 3 | 488 | Xiamen UniversityOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT01968213 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)(ARIEL3) | completed | Phase 3 | 564 | pharmaand GmbHINDUSTRY | 11 | Jun 9, 2023 | clinicaltrials |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | Phase 3 | 349 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | completed | Phase 3 | 596 | Tesaro, Inc.INDUSTRY | 15 | Jun 2, 2023 | clinicaltrials |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | terminated | Phase 3 | 93 | BayerINDUSTRY | 9 | May 3, 2023 | clinicaltrials |
| NCT02429687 | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors(MOGCT-01) | recruiting | Phase 3 | 129 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02429700 | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors(SCST-01) | recruiting | Phase 3 | 132 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03458221 | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER(STAPOVER) | recruiting | Phase 2 / Phase 3 | 148 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04792749 | Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer | unknown | Phase 3 | 77 | Samsung Medical CenterOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT03642132 | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | terminated | Phase 3 | 79 | PfizerINDUSTRY | 10 | Apr 6, 2023 | clinicaltrials |
| NCT00326456 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | unknown | Phase 3 | 820 | National Cancer Institute, NaplesOTHER | 3 | Mar 27, 2023 | clinicaltrials |
| NCT00660842 | Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer(MITO-7) | unknown | Phase 3 | 800 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer(MITO16MANGO2b) | unknown | Phase 3 | 406 | National Cancer Institute, NaplesOTHER | 5 | Mar 24, 2023 | clinicaltrials |
| NCT05255471 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.(MITO 35B) | recruiting | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05620355 | Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. | unknown | Phase 3 | 312 | Bio Genuine (Shanghai) Biotech Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT02853604 | Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer(AIM2CERV) | terminated | Phase 3 | 110 | Advaxis, Inc.INDUSTRY | 14 | Mar 14, 2023 | clinicaltrials |
| NCT05735145 | Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer | recruiting | Phase 3 | 108 | Fourth Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03038100 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(IMagyn050) | completed | Phase 3 | 1,301 | Hoffmann-La RocheINDUSTRY | 22 | Feb 17, 2023 | clinicaltrials |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)(OVAL) | completed | Phase 3 | 408 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | terminated | Phase 3 | 1,100 | MorphotekINDUSTRY | 30 | Dec 30, 2022 | clinicaltrials |
| NCT02733068 | A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. | completed | Phase 3 | 12,000 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 0 | Dec 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 12, 2024source: clinicaltrials